EGFR and non-small cell lung carcinoma: Preclinical studies demonstrated that targeted delivery of ChT drugs or EGFR-TKIs to NSCLC using EGFR–antibody conjugated NPs can enhance cytotoxicity and reduce off-target toxicity compared to free drugs.